Glaxo eyes credit crunch bargains as Q3 beats forecasts

By Ben Hirschler

LONDON (Reuters) - GlaxoSmithKline Plc's earnings beat analyst forecasts on Wednesday, helped by a weak pound, and the world's second biggest drugmaker said it was hunting for acquisition bargains thrown up by the credit crunch.

The fall in sterling flattered third-quarter results from the British group due to its reliance on overseas sales, softening the blow of generic competition to several older products and a further fall in sales of diabetes pill Avandia.

Earnings per share before restructuring charges rose 6 percent to 25.2 pence on sales up 7 percent at 5.88 billion pounds. Analysts polled by Thomson Reuters had on average forecast EPS of 24.3p.

Glaxo's top-selling drug Advair -- for asthma and chronic respiratory disease -- showed good growth in the third quarter while vaccine sales were stronger than expected.

Shares in Glaxo were 2 percent higher by 1245 GMT, reversing earlier losses.

The results highlight the relative resilience of large pharmaceutical companies to the economic downturn, following better than expected figures from Pfizer Inc -- the global leader -- on Tuesday.

"GSK's earnings remain defensive and relatively predictable in the context of macroeonomic uncertainty," said Deutsche Bank analyst Brian Bourdot.

"That said, the EPS decline in local currencies reflects the current struggle for growth GSK is experiencing, impacted by generic competition to leading brands."